wechat background

Follow the IASLC on WeChat

多年来,IASLC 一直依靠 LinkedIn、Facebook、Twitter 和 Instagram 等传统社交媒体平台让我们的听众了解 IASLC 的所有信息,包括即将召开的会议、我们最新的播客、网络研讨会和新的肺癌相关新闻。我们知道许多中国会员无法访问我们当前的社交平台。 这就是我们最近推出微信公众号的原因。 今天就扫描二维码关注我们吧!
2023 BOD Slider

2023 Candidates for Election to the IASLC Board of Directors

We are pleased to share that the IASLC Board of Directors has approved the slate of candidates for the 2023 IASLC Board election. Special thanks to the IASLC Nominating Committee for their work and to those members who participated in the nominations process.
2023 WCLC Abstract Submission

Early Registration for WCLC 2023 Is Now Open!

The IASLC invites you to be a part of IASLC’s ongoing success story and join us in Singapore for an exciting program with wide-ranging and multidisciplinary content.
Follow the IASLC on WeChat
2023 Candidates for Election to the IASLC Board of Directors
Early Registration for WCLC 2023 Is Now Open!


The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

ILCN In Focus

biomarker test report cover

Resources for Reading & Understanding Biomarker Test Results

Biomarker test results are crucial for lung cancer patients to understand, but they are difficult to read due to their complexity. The Advanced Practitioner Society for Hematology and Oncology, the Association of Community Cancer Centers,  the Association for Molecular Pathology, and LUNGevity Foundation created basic and comprehensive education for ALL non-small cell lung cancer patients to understand their results. Materials are available in English and Spanish. Learn more.

2022 Annual Report

2022 was a mix of old and new. Learn more about our work and see how IASLC members remain at the forefront of scientific achievement in multiple disciplines. 

IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer

IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer

The IASLC’s latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results from both a diagnostic and clinical perspective. 


Tobacco use is a well-established cause of cancer and contributes to about 1 in 3 cancer deaths. Whereas the harmful effects of smoking on health are well recognized, the negative impacts of continued smoking after a diagnosis of cancer are underappreciated. The substantial body of research reviewed in the 2014 US Surgeon General’s Report concluded that smoking by cancer patients and survivors causes adverse outcomes, including increased overall mortality and cancer-related mortality, greater risk of a second primary cancer, and associations with substantially worse toxicity from cancer treatments. The clinical effects of smoking after a cancer diagnosis also dramatically increase the cost of cancer care. The 2020 US Surgeon General’s Report reported that smoking cessation after a cancer diagnosis is associated with improved survival, and quitting smoking significantly benefits non-cancer-related health outcomes. The recommendations are available in English, Spanish, Portuguese, Japanese, Chinese, and Polish.

IASLC Corporate Roundtable

IASLC's Corporate Roundtable

Born from feedback received during meetings with our Corporate Partners in 2022, the IASLC Corporate Roundtable brings IASLC leadership and Roundtable Member Representatives together to collaborate on solutions to big-picture challenges facing those working to conquer lung cancer and other thoracic malignancies. 

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

See More

Our Work

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Lung Cancer Policy Network Map

Provide a global review of lung cancer screening clinical trials, implementation studies, and organized programs. This map facilitates policy-level discussions drawing from real-world implementation around the world and drives a community of learning around LDCT (Low Dose Computed Tomography) screening.

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.

Pathologic Response (PR) Project

Neoadjuvant therapies have unique advantages and opportunities in lung cancer and need further investigation. Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice. There is also a lack of precise definitions of the degree of pathologic response, including Major Pathologic Response (MPR) or Complete Pathologic Response (CPR). The IASLC PR Project was created to establish Pathologic Response (PR), Major Pathologic Response (MPR), and/or Complete Pathologic Response (CPR) in surgical resection specimens following neoadjuvant therapies as predictors of long-term clinical benefit in patients with resected stages I to III lung cancers. These recommendations are intended as guidance for clinical trials, although it is hoped they can be viewed as suggestions for good clinical practice outside of clinical trials, to improve the consistency of pathologic assessment of treatment response.

In numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
Years Experience
Number of Research Awards Funded
JTO Impact Factor

Upcoming Meetings & Webinars

Endorsed Event
Jun 26 - Jun 28 2023
June 26 - June 28
Endorsed Event
Jul 20 - Jul 21 2023
Thursday, July 19 - Friday, July 21, 2023
IASLC Meeting
Sep 09 - Sep 12 2023
CME Accredited
JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option.